- DuPont (DD, Financial) launches AmberChrom™ TQ1, a new agarose-based chromatography resin.
- The resin offers enhanced performance for oligonucleotide and peptide purification in biopharma applications.
- AmberChrom™ TQ1 is designed for both benchtop and large-scale commercial processes, enhancing purification efficiency with high purity outcomes.
In a strategic move to bolster its bioprocessing portfolio, DuPont (DD) has launched the DuPont™ AmberChrom™ TQ1 chromatography resin. This innovative agarose-based resin is tailored for the purification of oligonucleotides and peptides, addressing critical needs in biopharma applications. Notably, the resin boasts superior performance metrics, including increased loading capacity and throughput, with lower pressure requirements compared to its competitors.
The AmberChrom™ TQ1 resin is suitable for both benchtop scale and large-scale commercial purifications, delivering high-purity fractions and effectively removing impurities from target biomolecules. Its versatility allows for efficient handling of both DMT-Off and DMT-On oligonucleotides, offering high yield and purity essential for diverse manufacturing scenarios. The low-pressure operation further ensures the integrity of sensitive biomolecules during the purification process.
DuPont has validated the new resin's performance through comprehensive internal application studies using real-world drug feeds, showcasing its practical applicability and reducing implementation risk for potential users. Additionally, its compatibility with existing AmberChrom™ XT and CG chromatography resins facilitates a smoother integration into current processes, enhancing the overall bioprocessing suite offered by DuPont.
Shane Kendra, Global Bioprocessing Market Leader for DuPont Water Solutions, emphasized the importance of the launch: "The introduction of DuPont™ AmberChrom™ TQ1 chromatography resin supports the accelerated development and commercialization of oligonucleotide and peptide therapeutics." DuPont will further engage with its audience through an educational webinar on June 19, 2025, highlighting the resin's capabilities and its role in advancing biopharmaceutical manufacturing.
This development represents a significant step in strengthening DuPont's position within the growing biopharma manufacturing space, particularly as RNA-based therapies gain traction worldwide. More details about the AmberChrom™ TQ1 resin and its applications are available on DuPont's official website.
